Cologuard® revenue and completed tests increased 87 percent to $90.3 million and 186,000

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. LRCX
6. LVS
7. SAP
8. CSX
9. KNX
10. SPY

Go back to Cologuard® revenue and completed tests increased 87 percent to $90.3 million and 186,000

Exact Sciences (EXAS) Tops Q1 EPS by 4c

April 26, 2018 4:22 PM EDT

Exact Sciences (NASDAQ: EXAS) reported Q1 EPS of ($0.33), $0.04 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $90.3 million versus the consensus estimate of $86.93 million.

"The Exact Sciences team delivered strong growth to start the year by remaining relentlessly focused... More